SALT LAKE CITY, UT / ACCESSWIRE / February 10, 2015 / Some major shifts in government policy could soon dictate the state of the medical device industry, and investors should take note that these changes could give up-and-coming life sciences companies like Pressure Biosciences, Inc. (PBIO) the boost that helps them secure long-term market dominance. Last month, two of the most prominent Republicans in Congress, John Boehner and Mitch McConnell, announced that they have every intention of repealing a 2.3% excise tax on medical devices. Since the tax was part of the Affordable Care Act, its repeal is emblematic of Republicans' plans to bring an end to Obamacare. Now that Republicans have won the majority, it is only a matter of time before the repeal takes place.

Pressure Biosciences manufactures and sells machines equipped with its patented "Pressure Cycling Technology" (PCT). The machines are marketed to labs and other research facilities that use them to prepare bimolecular samples analyzed in all manner of scientific study, from forensics to pharmaceutical research.

PBIO, which is currently trending upward at .21 per share with a 4.7M market cap, already reported a promising 14% increase in its 3rd Quarter revenue for this year, and the company has seen steep jumps in revenue on a year to year basis each of the past three years. Pressure Biosciences stand to benefit from the tax repeal as the new policy should allow companies that manufacture these types of complex machines used for medical purposes to reach more customers and manufacture more products. Couple all this with the fact that biological sample preparation is a multi-billion dollar market that includes over a half million scientists, and PBIO profiles as a promising, low-risk entry into the life sciences market.

In addition to the tax repeal taking place in the U.S., another government policy change, this time in India, relaxed the country's foreign direct investment (FDI) standards to allow for greater investments on medical devices, which is an industry that has struggled to catch on in India until now. These new FDI laws also bode well for PBIO and other companies in the same market.

Another recent world event that has set the stage for a surge in the medical device industry is the ebola crisis. Alpha Pro Tech Ltd. (NYSE: APT), which trades at a reasonable 2.67 per share and manufacturers special protective equipment such as shields, a coverall suit, and respirator masks, experienced a huge bump in recent months with the ebola scares, and could rise sharply again with news of the tax repeal a possible resurgence of the virus.

Also leading the charge in the medical device industry alongside PBIO are a couple of companies that use technology-based treatments to promote health and improve quality of life for their patients. Enteromedics, Inc. (NASDAQ: ETRM), trading at 1.20 per share. ETRM grew by a whopping 25% in November, led by strong marketing and a solid technology, which fosters weight loss in patients by installing a pacemaker-like device to regulate the digestive system - a treatment that has shown impressive results. IsoRay, Inc. (NYSE: ISR) trades at 1.38 and also appears to be on the rise, having recently completed some successful trials in which its radiation device was implanted into a horse suffering from cancer.

Thanks to the above mentioned policy changes and many rapidly-evolving technologies at the disposal of many life sciences companies, the medical device industry continues to trend in the right direction. Several of the companies in this field succeed because they are able to offer the efficiency and ingenuity of advanced technologies to which none of their competitors have access. Pressure Biosciences is certainly no exception. Their PCT technology lies at the center of an exciting upswing in the life sciences industry.

DISCLAIMER:

Seraphim Strategies is a third party publisher. Not a registered broker/dealer/analyst/adviser, holds no investment licenses and may not sell, offer to sell or offer to buy any security. Market updates, news alerts and corporate profiles are not a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is not to be interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. For full disclaimer please read http://tomorrowsbluechips.com/disclaimer/ This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected", "anticipates", "draft", "eventually", or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements.


SOURCE: Seraphim Strategies